Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yaz is a combined oral contraceptive (COC) containing the progestin drospirenone (3 mg) and the synthetic estrogen ethinyl estradiol (0.02 mg). Drospirenone is a spironolactone analogue that possesses unique anti-mineralocorticoid and antiandrogenic properties, which distinguish it from other synthetic progestins. The drug works primarily by suppressing ovulation through the inhibition of gonadotropin secretion (FSH and LH). Yaz is FDA-approved for contraception, the treatment of moderate acne vulgaris, and the treatment of premenstrual dysphoric disorder (PMDD) in the general population. This specific clinical trial, led by St. Joseph's Healthcare Hamilton, evaluates the safety and efficacy of Yaz for treating PMDD specifically in women with comorbid bipolar disorder, a population that is frequently understudied and often excluded from standard hormonal contraceptive trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yaz.